A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications. READ MORE

From The Journal

Medicine changes rapidly, but you can always count on Journal of Clinical Pathways for the latest information on value-based care. READ MORE
October 15-18 marked the annual International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC). Oncologists from over 100 countries came together in Japan to discuss the latest developments and findings related to thoracic malignancy research. READ MORE
Journal of Clinical Pathways spoke with Dr Miller about a recent blog post, and how he sees future payment models adapting to an influx of costly new therapies as they enter the marker. READ MORE
New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease. READ MORE